Drug Profile
Cx 501
Alternative Names: Cx501Latest Information Update: 23 Jul 2015
Price :
$50
*
At a glance
- Originator Cellerix
- Developer TiGenix
- Class Cell therapies; Skin disorder therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Epidermolysis bullosa
Most Recent Events
- 31 Aug 2011 Cellerix is divesting Cx 501
- 05 May 2011 Cellerix has been acquired by TiGenix
- 19 Nov 2009 Cx 501 is still in phase II trials for Epidermolysis bullosa in Spain